SAFE Banking Act Clears First Hurdle: Should You Buy Canopy Growth (TSX:WEED) Stock Today?

The passing of the SAFE Banking Act in the U.S. could be a huge benefit to Canopy Growth Corp (TSX:WEED)(NYSE:CGC). Here’s why.

| More on:
Cannabis stocks have fallen.
You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Canadian marijuana stocks have endured a rough run in recent months, and the anticipation of the launch of the edibles market isn’t doing much to support the share prices.

One event that just occurred in the United States, however, might be a catalyst for the players who are positioned to take advantage of the possible legalization of cannabis sales in the United States at the federal level.

What’s the scoop?

The House of Representatives just passed the SAFE Banking Act, which is a bill that essentially gives cannabis companies in the United States access to traditional banking services.

The sale of marijuana is legal in many states, but remains illegal at the federal level. This has posed a major problem for cannabis companies, as they have been forced to use alternative lenders and non-bank financial partners to help launch and grow their businesses.

The passing of the bill now gives nearly 10,000 legal cannabis businesses in the United States the ability to use traditional banking services. This is viewed as an important step toward the eventual federal legalization of the sale of cannabis in the country.

The Senate still has to pass the SAFE Banking Act, but industry leaders are hoping it will get the green light, after strong bipartisan support in the House of Representatives.

How does this impact Canopy Growth?

Canopy Growth (TSX:WEED)(NYSE:CGC) has an agreement in place to acquire Acreage Holdings when it becomes legal in the United States at the federal level to cultivate, distribute, and possess marijuana. Canopy Growth paid US$300 million for the right to buy Acreage for US$3.4 billion.

Acreage is a major player in the U.S. cannabis industry with production and distribution facilities in 20 states. It had more than 80 dispensaries and 22 cultivation and processing sites when the deal was announced in April.

These markets are home to 180 million people. That’s roughly five times Canada’s population.

Should you buy Canopy Growth?

Canopy Growth is a leader in the Canadian cannabis industry and has an established presence in other key emerging global markets, including Europe and South America. The acquisition of Acreage would give it a head start on the U.S. market, in the event marijuana is legalized federally.

The passing of the SAFE Banking Act makes that possibility more likely, although it isn’t a guarantee.

At the time of writing, Canopy Growth trades for $32.50 per share and has a market capitalization of about $11 billion. The company still has the financial clout to expand and that would give Acreage a good boost in the race to scale up in the United States.

Canopy Growth is 38% owned by Constellation Brands, a U.S. beer, wine, and spirits giant with a market capitalization of U.S. $39 billion. The support of Constellation Brands should help Canopy Growth remain a leading player as the industry grows.

The company is still losing money and isn’t expected to turn a profit for some time. In addition, revenue came in in below analyst estimates in the most recent quarter. This is part of the reason the stock has remained under pressure.

I wouldn’t back up the truck, as we could see more downside in the sector before bargain hunters jump in and push share prices higher. That said, investors who are long-term cannabis bulls should have Canopy Growth in their portfolios.

Ongoing volatility should be expected, but it might be worthwhile to start nibbling while the stock is out of favour.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Andrew Walker has no position in any stock mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »